Cadila Healthcare's Moraiya facility, which was under the USFDA warning letter for the last few quarters, was re-inspected by the agency during February 6-15, 2017. Post inspection, the USFDA has not issued any Form 483 observations, thus giving clearance to the facility. This indicates the company will get an establishment inspection report (EIR) soon. The...